Company** | Product | Description | Indication | Type Action (Date) |
CANCER | ||||
Cel-Sci Corp. | Multikine | Natural mixture of | Treatment of head and | Announced preliminary |
human cytokines, | neck cancer prior to | results of small trial con- | ||
including interleukin-2 | surgery or radiation | ducted in Israel (5/6) | ||
therapy | ||||
Matritech Inc. | NMP22 | Diagnostic blood test | Aid in monitoring and | Approved for marketing |
Test Kit | that detects a nuclear | testing for high-risk, | in Japan (5/27) | |
matrix protein present | previously undiagnosed | |||
at elevated levels in | bladder cancer | |||
cancer cells | ||||
Progen | PI-88 | Retailored polysac- | Combination with | Initiated Phase I trials in |
Industries Ltd. | charide with a sulfate | chemotherapy for | Australia and U.K. (5/21) | |
(Australia) | chain attached; thought | treating various cancers | ||
to stop action of hep- | ||||
arinase (tumor cell | ||||
enzyme that allows | ||||
penetration of blood | ||||
vessels) | ||||
QLT PhotoThera- | Photofrin | Photosensitive drug | Treatment of certain | Presented results of Phase |
peutics Inc. | (FDA- | (porfimer sodium; | types of early- and late- | III trials conducted in |
(Canada) | approved) | produces toxic oxygen | stage non-small cell | North America and |
compound when | lung cancers | Europe at 34th annual | ||
light-activated) | meeting of the American | |||
Society of Clinical Onco- | ||||
logy (ASCO) in Los | ||||
Angeles (5/19) | ||||
Medarex Inc. | MDX-210 | Bispecific antibody | Late-stage prostate | Presented interim results |
that targets HER2 | and kidney cancer | of Phase II U.K. trial at | ||
receptor on certain | (patients pre-treated | ASCO meeting (5/19) | ||
cancer cells | with granulocyte | |||
macrophage-colony | ||||
stimulating factor) | ||||
Rhone-Poulenc | Taxotere | Docetaxel; semisyn- | Metastatic breast cancer | Results of Phase III trial |
Rorer Inc. | thetic agent derived | in patients who have | conducted in Canada and | |
(subsidiary of | from needles of the | progressed or relapsed | 16 other countries presen- | |
Rhone-Poulenc SA; | European yew tree; | after chemotherapy with | ted at ASCO meeting | |
NYSE:RP; France) | inhibits cancer cell | anthracycline | (5/18) | |
division by prevent- | ||||
ing assembly and | ||||
blocking disassembly | ||||
of microtubules | ||||
Xenova Group | XR9576 | Product derived from | Various cancers | Initiated Phase I trial in |
plc (U.K.) | naturally occurring | U.K. (5/12) | ||
compound; blocks P- | ||||
glycoprotein pump | ||||
(expels chemothera- | ||||
peutic drugs from | ||||
cancer cells) (injection) | ||||
CARDIOVASCULAR | ||||
Cypros | Cordox | Cardioprotective drug; | Treatment of both | European regulatory |
Pharmaceutical | (CPC-111) | small molecule com- | donor heart and | authorities approved pro- |
Corp. | pound designed to reduce | transplant recipient | tocol for Phase II trial in | |
accumulation of lactate; | in heart transplants | U.K. (5/27) | ||
facilitates anaerobic | ||||
glycolysis | ||||
Genetics Institute | ReFacto | Recombinant Factor | Hemophilia A | European Medicines |
Inc. and Wyeth- | VIII; albumin-free | Evaluation Agency | ||
Ayerst Pharma- | formulated product | accepted marketing auth- | ||
ceuticals (both | orization application for | |||
subsidiaries of Amer- | review (5/17) | |||
ican Home Products | ||||
Corp.;NYSE:AHP) | ||||
Molecular | Optison | 2nd-generation ultra- | Imaging agent for use | Approved for marketing |
Biosystems Inc. | sound contrast imaging | in patients with known | in all 15 member states of | |
and Mallinckrodt | agent; contains perflu- | or suspected cardio- | the European Union | |
Inc. (NYSE:MKG) | orocarbon | vascular disease | (5/19) | |
Northfield | PolyHeme | Chemically modified | Blood substitute; | Companies intend to get |
Laboratories Inc. | hemoglobin derived | direct replacement of | regulatory approvals for | |
and Pharmacia & | from outdated human | blood in large volumes | Phase III trials in U.K., | |
Upjohn AB (U.K.) | donor blood | in trauma setting | Germany and Sweden | |
(5/12) | ||||
CENTRAL NERVOUS SYSTEM | ||||
The Ares-Serono | Rebif | Recombinant interferon | Multiple sclerosis | Approved for marketing |
Group (Switzerland) | beta-1a | (relapsing-remitting; | in European Union (5/98) | |
also transitional) | ||||
Cephalon Inc. | Provigil | Modafinil; oral formu- | Narcolepsy (sleep | Approved for marketing |
lation of synthetic com- | disorder) | in Republic of Ireland | ||
pound that is thought to | (5/15) | |||
affect alpha-adrenergic | ||||
receptors in the brain | ||||
Neuroscience | DHEA | Dehydroepiandro- | Alzheimer's disease | Announced early comple- |
Pharma Inc. | sterone; neurosteroid | tion of patient enrollment | ||
(Canada; unit of | in 1st of 2 pivotal multi- | |||
Neurocrine | national Phase III trials | |||
Biosciences Inc.) | (5/4) | |||
INFECTION | ||||
Advanced Viral | Reticulose | Peptide-nucleic acid | Hiv infection and | Reported results of Phase |
Research Corp. | compound; stimulates | AIDS in treatment- | III trials conducted in | |
(NASDAQ:ADVR) | cytocidal arm of | naive patients | Barbados (5/21) | |
immune system and | ||||
activates production | ||||
of cytokines | ||||
BioChem Pharma | Lamivudine | Nucleoside analogue | Chronic hepatitis B | Glaxo Wellcome present- |
Inc. and Glaxo | (oral dosage) | virus infection | ed results of 2 internat- | |
Wellcome plc | ional trials (including | |||
(NYSE:GLX; U.K.) | in Asia) at Digestive Dis- | |||
ease Week (DDW) annual | ||||
meeting in New Orleans; | ||||
results show drug's effi- | ||||
cacy can be sustained for | ||||
2 years (5/17) | ||||
Cantab Pharma- | DISC HSV | Genetically disabled | Vaccine for treating | Presented data from Phase |
ceuticals plc and | herpes simplex virus | and preventing genital | I U.K. trials at 8th Inter- | |
Glaxo Wellcome | (replication-deficient | herpes | national Congress on | |
plc (NYSE:GLX; both | live virus) | Infectious Diseases in | ||
U.K.) | Boston (5/18) | |||
Isis Pharma- | Fomivirsen | Antisense inhibitor of | Newly diagnosed and | Filed marketing authori- |
ceuticals Inc. and | cytomegalovirus (CMV) | advanced CMV retinitis | zation application with | |
Ciba Vision Corp. | replication | in AIDS patients | European Agency for the | |
(unit of Novartis AG; | Evaluation of Medicinal | |||
Switzerland) | Products (5/5) | |||
North American | — | Polysaccharide | Group C meningo- | Presented preliminary |
Vaccine Inc. | conjugate vaccine | coccal infection in | results of 2 trials conduct- | |
infants, children and | in U.K. (one of which is | |||
young adults | a Phase II trial in infants) | |||
at the meeting of the | ||||
European Society of Pedi- | ||||
atric Infectious Diseases | ||||
(5/27) | ||||
SciClone | Zadaxin | Synthetic version of | Chronic hepatitis B | Results of Phase III trial |
Pharmaceuticals | (thymosin | naturally occurring pep- | virus infection | conducted in Taiwan |
Inc. | alpha 1) | tide hormone thymosin | published in 5/98 issue of | |
(immunomodulator) | Hepatology (5/29) | |||
SciClone Pharma- | Zadaxin | Synthetic version of | Chronic hepatitis B | Schering-Plough K.K. |
ceuticals Inc. and | (thymosin | naturally occurring pep- | virus infection | initiated pivotal Phase |
Schering-Plough | alpha 1) | tide hormone thymosin | III trial in Japan (5/12) | |
K.K. (Japan; sub- | (immunomodulator) | |||
sidiary of Schering- | ||||
Plough Corp.; NYSE: | ||||
SGP) | ||||
MISCELLANEOUS | ||||
Centocor Inc. | Infliximab | Chimeric monoclonal | Moderate-to-severe | Submitted marketing |
(formerly | antibody to tumor | Crohn's disease, includ- | authorization application | |
Avakine) | necrosis factor-alpha | ing fistulizing Crohn's | to European Agency for | |
disease | Evaluation of Medicinal | |||
Products (3/6)# | ||||
Hyal Pharma- | Solarase | 3% diclofenac gel | Actinic keratosis | Approved for marketing |
ceutical Corp. | (topical) | (precancerous skin | in Canada (5/20) | |
(TSE:HPC; Canada) | lesions caused by | |||
exposure to sun) | ||||
Icos Corp. | ICM3 | Monoclonal antibody | Psoriasis | Initiated Phase I/II trial in |
to ICAM-3 (molecule | Europe (5/20) | |||
found on T cells and | ||||
antigen-presenting | ||||
cells); prevents T-cell | ||||
activation | ||||
Pharming Holding | — | Transgenic human | Pompe's disease (a.k.a. | Initiated Phase I trial in |
NV (the Netherlands) | alpha-glucosidase; | glycogen storage dis- | the Netherlands (4/15)# | |
produced in milk of | order Type II) | |||
transgenic rabbits | ||||
Phytopharm plc | P54 | Botanical pharma- | Osteoarthritis | Initiated Phase II trial in |
(U.K.) | ceutical derived from | U.K. (5/6) | ||
medicinal plant; active | ||||
components down- | ||||
regulate production of | ||||
COX-2 (cyclo-oxygenase) | ||||
Zonagen Inc. and | Z-MAX | Immediate-release oral | Male erectile | Approved for marketing |
Schering-Plough | (a.k.a. | formulation of phentol- | dysfunction | in Mexico (5/29) |
Corp. (NYSE:SGP) | Vasomax) | amine mesylate | ||
NOTES: | ||||
This chart is intended to provide a monthly update on the clinical and regulatory status of biotech and biotech-related products in development in countries other than the U.S., whether those products are being developed by U.S.-based or non-U.S.-based firms. It covers events that were announced in May 1998, with the exception of items marked with #. | ||||
It does not cover ongoing clinical trials for which no news was issued in that month. | ||||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 19-20. |